A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer (Q40580007)

21 September 2017

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer (English)

1 reference

21 September 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

2

Ingo B Runnebaum

1 reference

21 September 2017

Richard E Buller

1

1 reference

21 September 2017

Beth Y Karlan

3

1 reference

21 September 2017

Jo Ann Horowitz

4

1 reference

21 September 2017

Mark Shahin

5

1 reference

21 September 2017

Thomas Buekers

6

1 reference

21 September 2017

Stan Petrauskas

7

1 reference

21 September 2017

Rolf Kreienberg

8

1 reference

21 September 2017

Dennis Slamon

9

1 reference

21 September 2017

Mark Pegram

10

1 reference

21 September 2017

1 July 2002

1 reference

21 September 2017

1 reference

21 September 2017

9

1 reference

21 September 2017

553-566

1 reference

21 September 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700472

21 September 2017

0 references

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Evaluation of treatment and survival after positive second-look laparotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

The p53 tumour suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Apoptosis, cancer and the p53 tumour suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Gene therapy: ovarian carcinoma as the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenoviral infectivity and p53 protein expression in gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Genetic mechanisms of tumor suppression by the human p53 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

CA 125 regression: a model for epithelial ovarian cancer response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Use of tumour markers in monitoring the course of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

Brain metastases in epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Tumor-suppressor p53: implications for tumor development and prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

p53 mutations and expression in ovarian cancers: correlation with overall survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Use of nitrogen mustard in treatment of serous effusions of neoplastic origin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Human adenovirus vectors for gene transfer into mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700472

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700472

1 reference

Dimensions Publication ID

21 September 2017

0 references

1 reference